Feb 17, 2021
Humacyte aims to transform medicine with off-the-shelf, universally implantable, bioengineered human tissue available at commercial scale. Transaction values Humacyte at a pre-money valuation of $800 million with existing Humacyte shareholders rolling over 100% of their equity into equity of the...
Jan 12, 2021
Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative...
Dec 09, 2020
DURHAM, N.C., Dec. 9, 2020 /PRNewswire/ -- Humacyte President and CEO Laura Niklason, M.D., Ph.D. will speak at the renowned Milken Institute Future of Health Summit on Wednesday, December 9 at 1:30 p.m. EST. Laura E. Niklason, MD Humacyte, Inc In a session entitled  Bringing It All Together:...
Oct 09, 2020
DURHAM, N.C., Oct. 9, 2020 /PRNewswire/ -- A new manuscript published in the highly cited scientific journal  Science  (also known as  Science Magazine ) reveals great strides in the field of regenerative medicine and vascular tissue engineering. Humacyte, Inc....
Displaying 101 - 110 of 111